单倍体造血干细胞移植联合供者来源的细胞因子诱导的杀伤细胞治疗自体造血干细胞移植后.

《单倍体造血干细胞移植联合供者来源的细胞因子诱导的杀伤细胞治疗自体造血干细胞移植后.》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、单倍体造血干细胞移植联合供者来源的细胞因子诱导的杀伤细胞治疗自体造血干细胞移植后复发的血液恶性肿瘤颜新宇唐晓琼刘林【摘要】目的观察单倍体造血干细胞移植联合供者来源的细胞因子诱导的杀伤细胞治疗自体干细胞移植后复发的血液恶性肿瘤的疗效。方法1例急性髓性內血病患者及1例T淋巴母细胞淋巴瘤/急性T淋巴细胞內血病患者经过常规化疗方案、自体移植后复发，对其实施单倍体造血干细胞移植。同时采集供者外周血单个核细胞在IFN-γ、IL-2、CD3单克隆抗体的刺激卜进行体外培养，获得细胞因子诱导的杀伤细胞，反复多次回输给患者。结果两例患者造血重建过程顺利，移植过程屮患者出现出血性膀胱炎。多次输注

2、细胞因子诱导的杀伤细胞后，患者出现局限性慢性移植物抗宿主病，骨髓持续完全缓解。结论供者来源的细胞因子诱导的杀伤细胞主要的效应细胞是CD3+CD56+细胞，CD8+细胞和干扰素-γ。它可以在单倍体造血干细胞移植后有效地清除微小残留病灶，延长无病生存期，而不加重移植物抗宿主病程度，值得进一步研究。【关键词】供者来源的细胞因子诱导的杀伤细胞；单倍体造血干细胞移植；移植物抗宿主病；急性髓性白血病；T淋巴母细胞淋巴瘤/急性T淋巴细胞Q血病Haploidenticalhematopoieticstemcelltransplantationcombinedwithdonor-derive

3、dcytokine-inducedkillercellssuccessfullytreatedthepatientswithhematologicmalignanciesrelapsingafterautologousstemcelltransplantation【Abstract】ObjectiveToinvestigatetheeffectofhaploidenticalhematopoieticstemcelltransplantationcombinedwithdonor-derivedcytokine-inducedkiller(CIK)cellstreatingthepat

4、ientswithhematologicmalignanciesrelapsingafterautologousstemcelltransplantation.MethodsOneacutemyeloidleukemiapatientandoneTlymphoblasticlymphoma/acuteTlymphoblasticleukemiapatientrelapsedposttheconventionalchemotherapiesandautologousstemcelltransplantation.Weappliedthehaploidenticalhematopoieti

5、cstemcelltransplantationimmediately.Consequently,usingcellseparatortoobtainthemobilizedperipheralbloodmononuclearcellsofdonors,thenCIKcellswereexpandedunderthestimulationwithIFN-γ,IL-2,OKT3.ResultsTheprocessoftwopatientsengraftedsuccessfully,theyhadhemorrhagiccystitisduringtheprocessoftran

6、splantation.Afterrepeatlyinfusionsofcytokine-inducedkillercells,graft-versus-hostdiseaseofpatientsdidn’taggravate.Theirbonemarrowskeepcontinuouscompleteremission.ConclusionsThemajorcytotoxiceffectorscellsofcytokine-inducedkillercellsareCD3positive,CD56positive,andCD8positivecellswithinterf

7、eron-γ.Theycouldeliminatetheresidualdiseaseandprolongdiseasefreesurvivaltime,withoutexacerbatinggraft-versus-hostdisease.Furtherexperiencesinadditionalpatientswithlongerfollow-uparenecessary.【Keywords】donor-derivedcyto